Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own44.17% Shs Outstand- Perf Week-2.00%
Market Cap38.37M Forward P/E- EPS next Y-0.61 Insider Trans-0.02% Shs Float43.72M Perf Month31.58%
Income- PEG- EPS next Q-0.21 Inst Own37.46% Short Float / Ratio0.20% / 1.93 Perf Quarter-50.51%
Sales- P/S- EPS this Y70.83% Inst Trans19.48% Short Interest0.09M Perf Half Y-58.12%
Book/sh0.88 P/B0.56 EPS next Y19.21% ROA- Target Price3.00 Perf Year-66.44%
Cash/sh1.11 P/C0.44 EPS next 5Y- ROE- 52W Range0.33 - 2.20 Perf YTD-56.25%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.73% Beta1.85
Dividend %- Quick Ratio6.95 Sales past 5Y- Gross Margin- 52W Low48.48% ATR0.04
Employees- Current Ratio6.95 Sales Q/Q- Oper. Margin0.00% RSI (14)52.65 Volatility7.09% 10.37%
OptionableYes Debt/Eq0.22 EPS Q/Q-54.96% Profit Margin- Rel Volume0.25 Prev Close0.50
ShortableYes LT Debt/Eq0.10 EarningsNov 09 AMC Payout- Avg Volume44.45K Price0.49
Recom2.00 SMA206.91% SMA502.68% SMA200-53.90% Volume11,243 Change-1.41%
Date Action Analyst Rating Change Price Target Change
Nov-18-22Initiated BofA Securities Neutral $2
Oct-25-22Initiated Credit Suisse Outperform $5
Sep-06-22Initiated Cowen Outperform
Nov-13-23 09:36AM
Nov-09-23 04:02PM
Oct-19-23 12:27PM
Oct-12-23 08:00AM
Oct-06-23 07:00AM
08:00AM Loading…
Sep-21-23 08:00AM
Sep-15-23 03:03AM
Sep-13-23 01:16PM
Aug-14-23 09:26AM
Aug-11-23 06:43AM
Aug-10-23 04:01PM
Jul-10-23 07:00AM
Jun-08-23 01:20PM
Jun-07-23 07:00AM
07:00AM Loading…
May-31-23 07:00AM
May-12-23 11:12AM
May-11-23 04:01PM
May-04-23 02:00AM
May-03-23 04:56PM
Apr-13-23 08:00AM
Mar-13-23 11:51AM
Mar-08-23 08:32AM
Mar-07-23 04:01PM
Feb-08-23 11:37AM
Feb-06-23 07:00AM
Feb-02-23 07:00AM
Jan-06-23 10:43AM
Jan-05-23 07:00AM
02:44PM Loading…
Dec-29-22 02:44PM
Dec-27-22 11:05AM
Dec-01-22 07:00AM
Nov-19-22 07:52AM
Nov-10-22 04:01PM
Nov-01-22 11:53AM
Oct-27-22 07:00AM
Oct-19-22 07:00AM
Sep-21-22 07:00AM
Sep-19-22 07:00AM
Aug-22-22 04:08PM
Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its leveraging technologies designed to directly target the brain establishes a new category of medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. The company is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martucci Walter Edward IIChief Executive OfficerSep 11Sale1.052,3532,4713,150,180Sep 14 08:30 AM
Franklin MatthewPresident & COOSep 11Sale1.051,7281,814753,898Sep 14 08:29 AM
Studer JacquelineChief Legal OfficerSep 11Sale1.051,1301,186348,292Sep 14 08:31 AM
Shanbhag SantoshChief Financial OfficerSep 11Sale1.05830872323,636Sep 14 08:28 AM